Bio-Rad Laboratories Inc. (BIO.B) on Wednesday reported a third-quarter loss of $341.9 million, after reporting a profit in the same period a ...

The outlook for full year 2025 remains unchanged at flat to 1% currency-neutral revenue growth, consistent with the Q2 update. Margins guidance is also unchanged. Q3 reported a slight revenue and ...

The company doesn't seem like it will generate pops in key fundamentals anytime soon.

Fintel reports that on October 30, 2025, Wells Fargo maintained coverage of Bio-Rad Laboratories (NYSE:BIO.B) with a Equal-Weight recommendation. Analyst Price Forecast Suggests 21.85% Upside As of ...

Bio-Rad Laboratories, Inc. BIO posted third-quarter 2025 adjusted earnings per share (EPS) of $2.26, which missed the Zacks ...

In context: Since its debut in 2005, Unity has become a fixture of modern game development, powering everything from Cuphead and Hollow Knight to Monument Valley and Genshin Impact. But a newly ...

A code execution vulnerability in the Unity game engine could be exploited to achieve code execution on Android and privilege escalation on Windows. Unity is a cross-platform game engine and ...

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. It operates through the ...

Unity patches CVE-2025-59489, a high-severity flaw enabling local code execution and data exposure Steam and Valve updated protections; publishers urged to rebuild or patch UnityPlayer.dll in games ...

A vulnerability found in the Unity game engine has led to studio Obsidian Entertainment taking down five of its games, including the premium edition of its 2025 release Avowed. The Unity issue, ...

Funds will advance Kernal Bio’s in vivo CAR T-cell therapy program and expand the capabilities of its mRNA 2.0 platform Program aims to improve cancer care by increasing the accessibility of advanced ...